RIVA-CLONAZEPAM 0.5 MG
CLONAZEPAM : 0.5 MG · DIN 02242077 · LABORATOIRE RIVA INC.
Health Canada status: DORMANT
What is RIVA-CLONAZEPAM?
RIVA-CLONAZEPAM 0.5 MG contains CLONAZEPAM : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02242077, held by LABORATOIRE RIVA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 22-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RIVA-CLONAZEPAM used for?
Management of myoclonic and akinetic seizures, petit mal variant (Lennox-Gastaut syndrome), and absence spells (petit mal) refractory to succinimides.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02242077 |
|---|---|
| Brand name | RIVA-CLONAZEPAM |
| Generic / active ingredient | CLONAZEPAM : 0.5 MG |
| Manufacturer | LABORATOIRE RIVA INC. |
| Strength | 0.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N03AE01 CLONAZEPAM |
| AHFS class | 28:12.08 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 22-Jul-2025 |
| Original market date | 2000-05-23 00:00:00 |
How is it administered?
Orally administered. Dosage must be individualised. Start with lowest possible dose in elderly. Gradual withdrawal is essential to avoid status epilepticus.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists page 20, but text ends at page 13).
How is it supplied?
Not explicitly detailed in provided text (mentions 0.5 mg and 2 mg strengths).
Contraindications
Hypersensitivity to benzodiazepines; severe respiratory insufficiency; severe hepatic impairment; sleep apnea syndrome; myasthenia gravis; narrow angle glaucoma.
Warnings and precautions
Risk of addiction, abuse, misuse; severe withdrawal symptoms; respiratory depression; suicidal ideation; risk of falls/fractures; potential for paradoxical increase in seizures.
What can be used instead?
Other Canadian products sharing ATC code N03AE01 CLONAZEPAM. 8 of 55 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CLONAZEPAM | 0.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02177889 |
| APO-CLONAZEPAM | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 02177897 |
| PMS-CLONAZEPAM | 0.25 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02179660 |
| PMS-CLONAZEPAM | 1 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02048728 |
| PMS-CLONAZEPAM | 2 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02048736 |
| PMS-CLONAZEPAM-R | 0.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02207818 |
| RIVOTRIL | 0.5 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 00382825 |
| RIVOTRIL | 2 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 00382841 |
| ACCEL-CLONAZEPAM | 0.5 MG | TABLET | ACCEL PHARMA INC | CANCELLED PRE MARKET | DIN 02365243 |
| ACCEL-CLONAZEPAM | 1.0 MG | TABLET | ACCEL PHARMA INC | CANCELLED PRE MARKET | DIN 02365251 |
Who else supplies CLONAZEPAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CLONAZEPAM appears in 1436 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.